Last reviewed · How we verify
Phase I Clinical Trial of TQC2731 Injection
This is the first-in-human phase 1 trial of TQC2731 injection in healthy subjects and in patients with severe asthma to evaluate the safety, tolerability, pharmacokinetic characteristics and immunogenicity.
Details
| Lead sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
|---|---|
| Phase | PHASE1 |
| Status | UNKNOWN |
| Enrolment | 96 |
| Start date | Fri Jun 25 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Aug 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Asthma Severe Persistent Controlled
Interventions
- TQC2731
- Placebo
Countries
China